Aniban, Rhofe P.

HRN: 21-28-10  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/22/2022
CEFTAZIDIME 1GM (VIAL)
04/22/2022
04/29/2022
IV
1gram
Q8hrs
Parapneumonic Process
Waiting Final Action 
04/22/2022
AZITHROMYCIN 500MG TABLET (TAB)
04/22/2022
04/24/2022
ORAL
500mg
OD
Pneumonia
Waiting Final Action 
04/25/2022
AZITHROMYCIN 500MG TABLET (TAB)
04/25/2022
04/28/2022
IV
500mg
OD
CAP MR
Waiting Final Action 
04/27/2022
AZITHROMYCIN 500MG TABLET (TAB)
04/27/2022
05/03/2022
PO
500mg
OD
Pleural Effusion
Waiting Final Action 
04/27/2022
CEFTAZIDIME 1GM (VIAL)
04/22/2022
05/05/2022
IV
1g
Q8
Pleural Effusion
Waiting Final Action 
04/29/2022
CLINDAMYCIN 150MG/ML, 4ML (AMP)
04/29/2022
05/06/2022
IV
600mg
Q8H
Pneumonia
Waiting Final Action 
05/03/2022
CEFTAZIDIME 1GM (VIAL)
05/03/2022
05/10/2022
IV
1g
Q8
Pleural Effusion
Waiting Final Action 
05/07/2022
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
05/07/2022
05/14/2022
IV
4.5g
Q6
CAP-HR
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: